The researchers hypothesize that SARS-CoV-2 infection may have triggered thymic inflammation, spearheading initial expression of muscle-like epitopes and T-cell dysregulation. Findings from a new case ...

Investigators conducted a case study of a patient who presented with COVID-19–induced seronegative myasthenia gravis, seeking more information on neurological manifestations of the respiratory disease ...

The Lancet Neurology has published data from the phase 3 MycarinG study evaluating the efficacy and safety of rozanolixizumab in adult patients with acetylcholine receptor autoantibody-positive ...

A study of 181 patients at 16 sites across the country who test negative for two antibodies long known to cause muscle-weakening myasthenia gravis, found that about 15% test positive for one of two ...

Please provide your email address to receive an email when new articles are posted on . Clinical-stage biopharmaceutical company Immunovant Inc. announced it has reached agreement with the FDA to ...

The first study to use an RNA-based chimeric antigen receptor T-cell (rCAR-T) therapy in autoimmune disease showed people with generalized myasthenia gravis tolerated the treatment well and ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.

Session: MGFA. This session, invited by the Myasthenia Gravis Foundation of America (MGFA) Medical and Scientific Advisory Committee (MSAC), features clinical and scientific experts sharing current ...